Compare PRAX & LLYVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | LLYVA |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.2B |
| IPO Year | 2020 | 2025 |
| Metric | PRAX | LLYVA |
|---|---|---|
| Price | $345.30 | $93.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $572.13 | N/A |
| AVG Volume (30 Days) | ★ 311.4K | 93.0K |
| Earning Date | 05-08-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $381,951,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7,758.26 | $5.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 12.18 |
| 52 Week Low | $37.25 | $74.38 |
| 52 Week High | $392.70 | $106.06 |
| Indicator | PRAX | LLYVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 35.98 |
| Support Level | $285.26 | $93.31 |
| Resistance Level | $356.02 | $99.16 |
| Average True Range (ATR) | 17.13 | 2.12 |
| MACD | -4.00 | -0.93 |
| Stochastic Oscillator | 21.92 | 3.97 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Liberty Live Holdings Inc consists of its ownership in Live Nation, its wholly owned subsidiary Quint and other minority investments. Quint is a provider of premium sports and entertainment experiences. Through exclusive rights agreements with sports leagues, event organizers, and governing bodies, Quint designs, develops, and sells official ticket-inclusive hospitality and single to multi-day experiential packages that may include on or off-site experiences, transportation, and hotel accommodations, with involvement of Quint personnel throughout the multi-day experiences. Live Nation is one of the live entertainment companies in the world, and the producer of live music concerts in the world, based on total fans that attend Live Nation events as compared to events of other promoters.